Philip Renaud, a Director, acquired 12,500,000 Common Shares on a direct ownership basis at a price of $0.120 through a private transaction on July 14th, 2017. The insider also acquired 12,500,000 Warrants with an exercise price of $0.180 for 18 months. This represents a $1,500,000 investment into the company's shares and an account share holdings change of greater than 100%.
In addition, Mark William Ahrens-Townsend, CEO and Subsidiary Executive, acquired 250,000 Common Shares and 250,000 Warrants on a direct ownership basis. This represents a $30,000 investment into the company's shares and an account share holdings change of 41.7%.
Kane Biotech is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's technologies include DispersinB, AloSera, Aledex, Strix NB, bluestem and KBI Disinfectant. It is focused on the companion animal market with Strix NB brand for the veterinary segment and bluestem brand for the pet over the counter (OTC) retail market. The Company markets its oral care technology into the Canadian pet specialty market under the bluestem brand. It has over 100 pet specialty stores in Canada, which are engaged in selling the bluestem oral health products. It has various formulations in development, including formulations with antibiotics and the antibiofilm enzyme beta-N-Acetylglucosaminidase and antibiofilm-antimicrobial formulations for both the veterinary and human markets. It is focused on the development of oral care spray formulation and a water additive powder formulation.
No Comments